2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate

We are 2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate CAS:143157-22-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate
CAS.NO:143157-22-6
Synonyms:2-deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate
2-deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoates
3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-ribofuranose
((2R,3R)-3-(benzoyloxy)-4,4-difluoro-5-hydroxytetrahydrofuran-2-yl)methyl benzoate
3,5-Di-O-benzoyl-2,2-difluoro-2-deoxyribose
Molecular Formula:C19H16F2O6
Molecular Weight:378.32400
 
Physical and Chemical Properties:
Density:1.41
Boiling point:495.925ºC
Flash point:253.726ºC
Index of Refraction:1.579
 
Specification:
Appearance:Off-white to pale yellow low melting solid or liquid
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Gemcitabine intermediate

2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate


Related News: At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.4H-3,1-benzoxazina-2,4 (1H) -diona CAS:118-48-9 At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.13633-25-5 At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.4433-79-8 Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.

Related Products
Product Name
Palmitoyl Tripepitde-5 View Details
Acetyl Hexapeptide-30 View Details
2,4-diphenyl-7,8-dihydro-6H-quinolin-5-one View Details
2,5-Dibromo-3-nitropyridine manufacturer Potassium azeloyl diglycinate manufacturer N-Glycyl-L-tyrosine manufacturer Glycyrrhizic Acid Dipotassium Salt Hydrate manufacturer Saikosaponin D manufacturer